Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 9/20 | 0.54 |
| ▸ | CDK1 | P06493 | 5/20 | 0.52 |
| ▸ | CCNB2 | O95067 | 4/20 | 0.52 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.52 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 0.52 |
| ▸ | CDK2 | P24941 | 1/20 | 0.52 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.43 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.43 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19370351 | 0.95 | NT5E (0.50) | NT5ECDK1CCNB2CCNB1CCNB3 | |
| SCHEMBL19370287 | 0.93 | CCNB2 (0.47) | NT5ECDK1CCNB2CCNB1CCNB3 | |
| SCHEMBL19370337 | 0.90 | CDK2 (0.45) | NT5ECDK1CCNB2CCNB1CCNB3 | |
| SCHEMBL22214990 | 0.89 | CDK1 (0.55) | NT5ECDK1CCNB2CCNB1CCNB3 | |
| SCHEMBL19370191 | 0.89 | NT5E (0.57) | NT5ECDK1CDK2 | |
| SCHEMBL22843545 | 0.88 | CDK1 (0.54) | NT5ECDK1CCNB2CCNB1CCNB3 | |
| SCHEMBL19370192 | 0.87 | NT5E (0.58) | NT5ECDK1CCNB1 | |
| SCHEMBL24078875 | 0.87 | NT5E (0.47) | NT5ECDK1CDK2 | |
| SCHEMBL19370203 | 0.87 | NT5E (0.52) | NT5ECDK1CCNB1 | |
| SCHEMBL19370202 | 0.87 | CDK2 (0.47) | NT5ECDK1CCNB2CCNB1CCNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10981944-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ARCUS BIOSCIENCES, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20190309010-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. | 2019-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981944-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ENTPD5, NT5C2, NT5E | NT5E 3/4885CDK1 3650/4885CCNB2 4718/4885 |
| US-20190309010-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ENTPD5, NT5C2, NT5E | NT5E 3/4885CDK1 3655/4885CCNB2 4732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.